# Oslo University Hospital: Phase 2 study terminated, 39 enrolled (Colorectal Cancer, Liver Metastases)

**Score:** 40/100

| Field | Value |
|---|---|
| Sponsor | Oslo University Hospital |
| Sponsor type | Academic and hospital |
| Study | HAI-Floxuridine, or Liver-Tx, Combined With 2nd Line Chemotherapy Versus 2nd Line Chemotherapy Alone for Patients With Colorectal Liver Metastases and Heavy Tumour Burden. |
| NCT ID | NCT04898504 |
| Phase | Phase 2 |
| Status | terminated |
| Conditions | Colorectal Cancer; Liver Metastases; Chemotherapy Effect |
| Intervention types | drug, procedure |
| Target enrollment | 39 |
| Site countries | Norway |
| Posted | 2021-05-24 |
| Planned start | 2021-08-23 |
| Event | Terminated |
| Event date | 2026-08-20 |
| Last update posted | 2026-10-22 |

## Why this score
- Stopped early: budget and sites freed up.
- Phase 2: multi-site, larger budget.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT04898504). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.